Literature DB >> 17723255

Clinical and pathological features of an Alzheimer's disease patient with the MAPT Delta K280 mutation.

Parastoo Momeni1, Alan Pittman, Tammaryn Lashley, Jana Vandrovcova, Elke Malzer, Connie Luk, Christine Hulette, Andrew Lees, Tamas Revesz, John Hardy, Rohan de Silva.   

Abstract

We identified a case of Alzheimer's disease with a deletion of the lysine residue at codon 280 (DeltaK280) in exon 10-encoded microtubule-binding repeat domain of the tau gene (MAPT). This mutation was originally identified in a sporadic case of frontotemporal dementia (FTD) with a family history of Parkinson's disease. In the original report, the authors were careful in their assessment of the pathogenicity and suggested one could not be sure whether the mutation was pathogenic or not. The mutation has always presented a conundrum because it is the only known mutation, of assumed pathogenicity, which increases the proportion of 3-repeat tau mRNA in in vitro assays. Here we present the clinical and pathological features of a new case with this mutation and discuss whether the mutation is indeed pathogenic.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17723255      PMCID: PMC2666148          DOI: 10.1016/j.neurobiolaging.2007.07.013

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  22 in total

1.  "Missing" tau mutation identified.

Authors:  M Hutton
Journal:  Ann Neurol       Date:  2000-04       Impact factor: 10.422

2.  The complex relationship between soluble and insoluble tau in tauopathies revealed by efficient dephosphorylation and specific antibodies.

Authors:  D P Hanger; G M Gibb; R de Silva; A Boutajangout; J-P Brion; T Revesz; A J Lees; B H Anderton
Journal:  FEBS Lett       Date:  2002-11-20       Impact factor: 4.124

3.  Staging of brain pathology related to sporadic Parkinson's disease.

Authors:  Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

4.  The DeltaK280 mutation in MAP tau favors exon 10 skipping in vivo.

Authors:  John C van Swieten; Iraad F Bronner; Asma Azmani; Lies-Anne Severijnen; Wouter Kamphorst; Rivka Ravid; Patrizia Rizzu; Rob Willemsen; Peter Heutink
Journal:  J Neuropathol Exp Neurol       Date:  2007-01       Impact factor: 3.685

5.  Distinct FTDP-17 missense mutations in tau produce tau aggregates and other pathological phenotypes in transfected CHO cells.

Authors:  V Vogelsberg-Ragaglia; J Bruce; C Richter-Landsberg; B Zhang; M Hong; J Q Trojanowski; V M Lee
Journal:  Mol Biol Cell       Date:  2000-12       Impact factor: 4.138

6.  A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis.

Authors:  S G Greenberg; P Davies
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

7.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

8.  Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure.

Authors:  M von Bergen; S Barghorn; L Li; A Marx; J Biernat; E M Mandelkow; E Mandelkow
Journal:  J Biol Chem       Date:  2001-10-17       Impact factor: 5.157

9.  Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms.

Authors:  M Goedert; M G Spillantini; N J Cairns; R A Crowther
Journal:  Neuron       Date:  1992-01       Impact factor: 17.173

10.  Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies.

Authors:  R de Silva; T Lashley; G Gibb; D Hanger; A Hope; A Reid; R Bandopadhyay; M Utton; C Strand; T Jowett; N Khan; B Anderton; N Wood; J Holton; T Revesz; A Lees
Journal:  Neuropathol Appl Neurobiol       Date:  2003-06       Impact factor: 8.090

View more
  28 in total

Review 1.  New approaches to genetic counseling and testing for Alzheimer's disease and frontotemporal degeneration.

Authors:  Jill S Goldman
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

2.  Early-Onset Alzheimer Disease and Candidate Risk Genes Involved in Endolysosomal Transport.

Authors:  Brian W Kunkle; Badri N Vardarajan; Adam C Naj; Patrice L Whitehead; Sophie Rolati; Susan Slifer; Regina M Carney; Michael L Cuccaro; Jeffery M Vance; John R Gilbert; Li-San Wang; Lindsay A Farrer; Christiane Reitz; Jonathan L Haines; Gary W Beecham; Eden R Martin; Gerard D Schellenberg; Richard P Mayeux; Margaret A Pericak-Vance
Journal:  JAMA Neurol       Date:  2017-09-01       Impact factor: 18.302

Review 3.  Disrupting self-assembly and toxicity of amyloidogenic protein oligomers by "molecular tweezers" - from the test tube to animal models.

Authors:  Aida Attar; Gal Bitan
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

4.  C9orf72 hexanucleotide repeat expansions in clinical Alzheimer disease.

Authors:  Matthew Harms; Bruno A Benitez; Nigel Cairns; Breanna Cooper; Paul Cooper; Kevin Mayo; David Carrell; Kelley Faber; Jennifer Williamson; Tom Bird; Ramon Diaz-Arrastia; Tatiana M Foroud; Bradley F Boeve; Neill R Graff-Radford; Richard Mayeux; Sumitra Chakraverty; Alison M Goate; Carlos Cruchaga
Journal:  JAMA Neurol       Date:  2013-06       Impact factor: 18.302

Review 5.  Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia.

Authors:  Edward D Huey; Nicole Armstrong; Parastoo Momeni; Jordan Grafman
Journal:  Expert Opin Ther Targets       Date:  2008-11       Impact factor: 6.902

6.  Correction of tau mis-splicing caused by FTDP-17 MAPT mutations by spliceosome-mediated RNA trans-splicing.

Authors:  Teresa Rodriguez-Martin; Karen Anthony; Mariano A Garcia-Blanco; S Gary Mansfield; Brian H Anderton; Jean-Marc Gallo
Journal:  Hum Mol Genet       Date:  2009-06-04       Impact factor: 6.150

Review 7.  Alzheimer's disease genetics: from the bench to the clinic.

Authors:  Celeste M Karch; Carlos Cruchaga; Alison M Goate
Journal:  Neuron       Date:  2014-07-02       Impact factor: 17.173

8.  Adenosine A1 receptor antagonist rolofylline alleviates axonopathy caused by human Tau ΔK280.

Authors:  Frank J A Dennissen; Marta Anglada-Huguet; Astrid Sydow; Eckhard Mandelkow; Eva-Maria Mandelkow
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-26       Impact factor: 11.205

9.  Pathological Tau Promotes Neuronal Damage by Impairing Ribosomal Function and Decreasing Protein Synthesis.

Authors:  Shelby Meier; Michelle Bell; Danielle N Lyons; Jennifer Rodriguez-Rivera; Alexandria Ingram; Sarah N Fontaine; Elizabeth Mechas; Jing Chen; Benjamin Wolozin; Harry LeVine; Haining Zhu; Jose F Abisambra
Journal:  J Neurosci       Date:  2016-01-20       Impact factor: 6.167

10.  The Potential of Indole/Indolylquinoline Compounds in Tau Misfolding Reduction by Enhancement of HSPB1.

Authors:  Kuo-Hsuan Chang; Chih-Hsin Lin; Hsuan-Chiang Chen; Hsin-Yu Huang; Shu-Ling Chen; Te-Hsien Lin; Chintakunta Ramesh; Chin-Chang Huang; Hon-Chung Fung; Yih-Ru Wu; Hei-Jen Huang; Guey-Jen Lee-Chen; Hsiu Mei Hsieh-Li; Ching-Fa Yao
Journal:  CNS Neurosci Ther       Date:  2016-07-18       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.